**Amendments to the Claims**

Please amend Claims 1, 2, 12, 72 and 74. Please add new Claims 76 - 83. Please cancel without prejudice Claims 3, 22-30 and 46-71, previously withdrawn. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A pharmaceutical composition, comprising either a single pharmaceutical agent, wherein the single pharmaceutical agent is represented by Formula (I) or a compound represented by Formula (I) in combination with one or more of an antibacterial agent, an anti-viral agent, an anti-inflammatory agent and an antibiotic agent ~~compound having the following formula~~:




;

(I)

wherein G1 is selected from the group consisting of ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, aryl group or a heteroaryl group, wherein the aryl or heteroaryl is a ring having 5, 6, or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein G2 is a group having a neutral or a net charge, selected from the following: -CN ($R_1R_2R_3$), -CN ($R_1R_2$), -N($R_1R_2R_3$), -N($R_1R_2$), or heteroaryl group, wherein the heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein $R_1$, $R_2$ and $R_3$ independent of one another are selected from the group consisting of -H, -$CH_3$, -$CH_2CH_3$,

or other linear alkyl group ~~such as propyl, butyl, or pentyl,~~ wherein G3 and G4 independent of one another are selected from the group consisting of N, S, O, ($C_1$-$C_6$) alkyl, and ($C_1$-$C_6$) alkenyl, wherein X is a ($C_1$-$C_{12}$) alkyl and wherein Z is present as a charged species when $G_2$ has a net charge, the charge of Z depends on the charge of $G_2$, Z is absent when G2 is neutral in charge; and a pharmaceutically acceptable carrier~~; and optionally one or more other pharmaceutically active ingredients selected from the group consisting of an antibacterial, an anti-viral, an anti-inflammatory agent and an antibiotic~~.

2. (Currently Amended) A pharmaceutical tablet composition comprising either a pharmaceutically effective amount of a single pharmaceutical agent *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof in ~~combination with~~ a pharmaceutically acceptable carrier or a pharmaceutically effective amount of *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof ~~and wherein the pharmaceutical tablet optionally comprises~~ in combination with one or more ~~other pharmaceutically active~~ ingredients selected from the group consisting of an antibacterial, an anti-viral, an anti-inflammatory agent and an antibiotic.

3. (Cancelled)

4. (Original) The composition of claim 1, wherein the compound is 5-50% by weight of the composition.

5-8. (Cancelled)

9. (Original) The composition of claim 1, wherein the compound has the following formula:




10. (Original) The composition of claim 9, wherein the compound has the following formula:




wherein each R is independently selected from the group consisting of hydrogen, ($C_1$-$C_6$) alkyl, and ($C_1$-$C_6$) alkenyl.

11. (Original) The composition of claim 1, further comprising a sustained release delivery system and wherein the composition is formulated to release the compound over a period of at least 2 hours.

12. (Currently Amended) The composition of claim [[1]] 11, wherein the sustained release delivery system is a microencapsulated product.

13. (Original) The composition of claim 11, wherein the sustained release delivery system is a sustained release capsule.

14. (Original) The composition of claim 11, wherein the sustained release delivery system is a fatty acid carrier.

15. (Original) The composition of claim 14, wherein the fatty acid carrier includes $C_9$-$C_{20}$ fatty acids.

16. (Original) The composition of claim 11, wherein the sustained release delivery system is a microparticle.

17. (Original) The composition of claim 11, wherein the sustained release delivery system is a medicinal pump.

18. (Original) The composition of claim 11, wherein the sustained release delivery system is formulated to release the compound over a period of at least 12 hours.

19. (Original) The composition of claim 11, wherein the sustained release delivery system is formulated to release the compound over a period of at lest 24 hours.

20. (Original) The composition of claim 11, wherein the sustained release delivery system is formulated to release the compound over a period of at least 2 days.

21. (Original) The composition of claim 11, wherein the sustained release delivery system is formulated to release the compound over a period of at least 7 days.

22-30. (Cancelled)

31-45. (Cancelled)

46-71. (Cancelled)

72. (Currently Amended) A pharmaceutical injectable composition comprising either a pharmaceutically effective amount of a single pharmaceutical agent *N*-ethyl-*N'*-(3-

dimethylaminopropyl) urea or a salt thereof in ~~combination with~~ a pharmaceutically acceptable sterile liquid carrier ***or*** a pharmaceutically effective amount of *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof ~~; and wherein the composition optionally comprises~~ in combination with one or more other pharmaceutically active ingredients selected from the group consisting of an antibacterial, an anti-viral, an anti-inflammatory agent and an antibiotic.

73. (Cancelled)

74. (Currently Amended) A pharmaceutical composition comprising an aerolsol form of either a pharmaceutically effective amount of a single pharmaceutical agent *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof ~~; and wherein the pharmaceutical composition optionally comprises~~ ***or*** a pharmaceutically effective amount of *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof in combination with one or more other pharmaceutically active ingredients selected from the group consisting of an antibacterial, an anti-viral, an anti-inflammatory agent and an antibiotic.

75. (Previously Presented) The pharmaceutical composition of claim 72 wherein the pharmaceutically acceptable sterile liquid liquid carrier is isotonic.

76. (New) The pharmaceutical composition of Claim 1 wherein the pharmaceutical composition is a tablet.

77. (New) The pharmaceutical composition of Claim 1 wherein the pharmaceutical composition is an aerosol.

78. (New) The pharmaceutical composition of Claim 1 wherein the carrier is sterile water.

79. (New) A pharmaceutical composition, consisting essentially of a pharmaceutically acceptable carrier and a compound having the following formula (I):




(I);

wherein G1 is selected from the group consisting of ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, aryl group or a heteroaryl group, wherein the aryl or heteroaryl is a ring having 5, 6, or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom,

wherein G2 is a group having a neutral or a net charge, selected from the following: -CN ($R_1R_2R_3$), -CN ($R_1R_2$), -N($R_1R_2R_3$), -N($R_1R_2$), or heteroaryl group, wherein the heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein $R_1$, $R_2$ and $R_3$ independent of one another are selected from the group consisting of -H, -$CH_3$, -$CH_2CH_3$, or other linear alkyl group,

wherein G3 and G4 independent of one another are selected from the group consisting of N, S, O, ($C_1$-$C_6$) alkyl, and ($C_1$-$C_6$) alkenyl,

wherein X is a ($C_1$-$C_{12}$) alkyl and wherein Z is present as a charged species when $G_2$ has a net charge, the charge of Z depends on the charge of $G_2$, Z is absent when G2 is neutral in charge; and

wherein the pharmaceutically acceptable carrier is sterile water.

80. (New) The composition of Claim 79 wherein the compound of formula (I) is of *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof.

81. (New) A pharmaceutical composition consisting essentially of a pharmaceutical agent represented by Formula (I) and a compound selected from one or more of an antibacterial agent, an anti-viral agent, an anti-inflammatory agent and an antibiotic agent in a pharmaceutically acceptable carrier, wherein Formula (I) is




(I);

wherein G1 is selected from the group consisting of ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, aryl group or a heteroaryl group, wherein the aryl or heteroaryl is a ring having 5, 6, or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom,

wherein G2 is a group having a neutral or a net charge, selected from the following: -CN ($R_1R_2R_3$), -CN ($R_1R_2$), -N($R_1R_2R_3$), -N($R_1R_2$), or heteroaryl group, wherein the heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein $R_1$, $R_2$ and $R_3$ independent of one another are selected from the group consisting of -H, -$CH_3$, -$CH_2CH_3$, or other linear alkyl group,

wherein G3 and G4 independent of one another are selected from the group consisting of N, S, O, ($C_1$-$C_6$) alkyl, and ($C_1$-$C_6$) alkenyl; and

wherein X is a ($C_1$-$C_{12}$) alkyl and wherein Z is present as a charged species when $G_2$ has a net charge, the charge of Z depends on the charge of $G_2$, Z is absent when G2 is neutral in charge.

82. (New) The composition of Claim 80 wherein the compound of formula (I) is of *N*-ethyl-*N'*-(3-dimethylaminopropyl) urea or a salt thereof.

83. (New) The pharmaceutical composition of Claim 1 comprising a compound represented by Formula (I) in combination with one or more of an antibacterial agent, an anti-viral agent, an anti-inflammatory agent and an antibiotic agent.